文献速递胃肠外科围术期管理与 ERAS

胃癌新辅助化疗后肿瘤降期决定手术生存

Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
PubMed 文献 · Surgery · 2021-09-22

该回顾性研究纳入1996至2016年491例接受根治性手术的胃或食管胃结合部腺癌患者,最终分析449例,其中163例(36.3%)接受新辅助化疗,61例(37.4%)出现肿瘤降期。

要点

  • 新辅助化疗后肿瘤降期是胃癌根治术后总生存和无病生存的独立预后因素。
  • 临床分期准确性低,cT1-T2N0直接手术患者中45.5%被低估分期。
  • 因缺乏降期预测因素且分期准确性低,围手术期化疗指征应保持宽泛。

核心结论

  • 新辅助化疗后的肿瘤降期是胃癌根治术后总生存和无病生存的主要预后因素。

研究设计与样本

  • 单中心回顾性研究,纳入1996至2016年491例接受根治性手术的胃或食管胃结合部腺癌患者,最终分析449例。

主要发现

  • 163例(36.3%)接受新辅助化疗的患者中,61例(37.4%)出现肿瘤降期。
  • 45.5%的cT1-T2N0直接手术患者被低估分期,病理分析显示肿瘤更晚期。

临床怎么用

  • 新辅助化疗后评估肿瘤降期有助于判断胃癌根治术后的生存预后。
  • 鉴于临床分期准确性低且缺乏降期预测因素,围手术期化疗的指征应保持宽泛。

局限性

  • 本研究为单中心回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2006, surgery combined with perioperative chemotherapy is the standard of care for resectable gastric adenocarcinoma in Europe. Specific effects of neoadjuvant chemotherapy remain unknown. The aim was to evaluate the rate of tumor downstaging and its impact on survival in patients undergoing curative resection after neoadjuvant chemotherapy (NeoCT) for gastric adenocarcinoma. MATERIAL AND METHODS: All patients treated in a curative intent for gastric or esophagogastric junction adenocarcinomas between 1996 and 2016 in our high-volume center were retrospectively included. Tumor downstaging after NeoCT was defined as ypTN inferior to cTN. The accuracy of clinical staging was evaluated in patients treated by upfront surgery before 2006. RESULTS: During the study period, 491 patients were operated for gastric adenocarcinoma, and 449 patients were finally analyzed. Among the 163 (36.3%) patients who received NeoCT, 61 (37.4%) had tumor downstaging. Overall survival and disease-free survival were longer in patients with tumor downstaging compared to patients without it (5-year survival: 84.8% vs 49.7%; P = .002 and 61.7% vs 43.4%; P = .054). In multivariate analysis tumor downstaging was an independent prognosis factor for better overall survival (HR = 5.258; P = .002) and disease-free survival (HR = 2.286; P = .028). Moreover, 45.5% of patients staged cT1-T2N0, in whom upfront surgery was performed, were understaged and ultimately had a more advanced tumor on pathological analysis. CONCLUSION: Response to neoadjuvant chemotherapy constitutes a major prognostic factor for overall and disease-free survival. In the absence of predictive factors for tumor downstaging, the indication for perioperative chemotherapy should remain broad, in particular because of the low accuracy of pretherapeutic staging and therefore the high risk of understaging tumors.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Levenson G, Voron T, Paye F, et al. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma. Surgery. 2021. PMID: 34561115. doi:10.1016/j.surg.2021.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。